Corindus Vascular Robotics Inc (CVRS) Short Interest Down 2.8% in December

Corindus Vascular Robotics Inc (NYSEAMERICAN:CVRS) saw a large decline in short interest during the month of December. As of December 29th, there was short interest totalling 11,613,722 shares, a decline of 2.8% from the December 15th total of 11,945,130 shares. Based on an average daily trading volume, of 542,589 shares, the days-to-cover ratio is presently 21.4 days. Currently, 12.6% of the shares of the stock are short sold.

Shares of Corindus Vascular Robotics (CVRS) opened at $1.03 on Friday. The firm has a market capitalization of $194.36, a P/E ratio of -4.29 and a beta of 19.49. Corindus Vascular Robotics has a 12-month low of $0.40 and a 12-month high of $2.25.

Corindus Vascular Robotics (NYSEAMERICAN:CVRS) last announced its quarterly earnings data on Tuesday, November 7th. The medical equipment provider reported ($0.04) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.05) by $0.01. Corindus Vascular Robotics had a negative return on equity of 110.93% and a negative net margin of 323.84%. The firm had revenue of $2.43 million during the quarter, compared to the consensus estimate of $3.60 million.

A number of analysts recently weighed in on the company. Zacks Investment Research downgraded Corindus Vascular Robotics from a “buy” rating to a “hold” rating in a research report on Friday. ValuEngine downgraded Corindus Vascular Robotics from a “hold” rating to a “sell” rating in a research report on Tuesday, October 3rd. Finally, BidaskClub downgraded Corindus Vascular Robotics from a “sell” rating to a “strong sell” rating in a research report on Wednesday, October 11th. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and two have issued a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $2.33.

A number of hedge funds have recently made changes to their positions in the business. Schwab Charles Investment Management Inc. lifted its position in Corindus Vascular Robotics by 34.2% in the third quarter. Schwab Charles Investment Management Inc. now owns 383,800 shares of the medical equipment provider’s stock valued at $584,000 after purchasing an additional 97,900 shares during the last quarter. Essex Investment Management Co. LLC bought a new stake in Corindus Vascular Robotics in the third quarter valued at approximately $1,213,000. California State Teachers Retirement System lifted its position in Corindus Vascular Robotics by 34.4% in the second quarter. California State Teachers Retirement System now owns 148,558 shares of the medical equipment provider’s stock valued at $276,000 after purchasing an additional 38,000 shares during the last quarter. State Street Corp lifted its position in Corindus Vascular Robotics by 44.3% in the second quarter. State Street Corp now owns 926,439 shares of the medical equipment provider’s stock valued at $1,724,000 after purchasing an additional 284,507 shares during the last quarter. Finally, Goldman Sachs Group Inc. lifted its position in Corindus Vascular Robotics by 147.8% in the second quarter. Goldman Sachs Group Inc. now owns 58,824 shares of the medical equipment provider’s stock valued at $109,000 after purchasing an additional 35,086 shares during the last quarter.

ILLEGAL ACTIVITY NOTICE: This article was published by The Lincolnian Online and is the property of of The Lincolnian Online. If you are reading this article on another website, it was illegally stolen and republished in violation of international copyright and trademark laws. The legal version of this article can be read at https://www.thelincolnianonline.com/2018/01/14/corindus-vascular-robotics-inc-cvrs-short-interest-down-2-8-in-december.html.

About Corindus Vascular Robotics

Corindus Vascular Robotics, Inc is engaged in robotic-assisted vascular interventions. The Company’s CorPath System is a medical device that brings robotic-assisted precision to radial, coronary and peripheral procedures. The workstation allows the physician greater control and the freedom from wearing heavy lead protective equipment that causes musculoskeletal injuries.

Receive News & Ratings for Corindus Vascular Robotics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corindus Vascular Robotics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply